FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial
(See required screening study ECOG-ACRIN EAY191)
EAY191-A6 reopened to accrual, effective April 3, 2025.